Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00167154 · ClinicalTrials.gov registry record · Phase 3
Risperidone and Suicidality in Major Depressive Disorder
A Phase 3 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00167154 is a Phase 3 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 30 participants.
The verdict
NCT00167154, a Phase 3 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this trial is to investigate the efficacy of risperidone as an adjunct to an antidepressant treatment in the acute management of suicidality during an episode of major depressive disorder.
Interventions
- DRUG Risperidone and placebo comparator
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-06 |
| Est. Completion | 2008-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00167154
The ClinicalTrials.gov registry entry for NCT00167154 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperidone and placebo comparator is the first listed.
NCT00167154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00167154 about?
NCT00167154 is a clinical study titled "Risperidone and Suicidality in Major Depressive Disorder". The purpose of this trial is to investigate the efficacy of risperidone as an adjunct to an antidepressant treatment in the acute management of suicidality during an episode of major depressive disorder.
What is the current status of trial NCT00167154?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2004-06. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00167154?
The interventions under investigation include: Risperidone and placebo comparator (DRUG).
Who is sponsoring clinical trial NCT00167154?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.